CRIS Current Research Information System

RASCHI, EMANUEL
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.095
EU - Europa 5.065
AS - Asia 2.885
AF - Africa 431
OC - Oceania 29
SA - Sud America 25
Continente sconosciuto - Info sul continente non disponibili 3
Totale 15.533
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.054
GB - Regno Unito 1.373
IT - Italia 1.257
CN - Cina 887
SG - Singapore 808
DE - Germania 673
VN - Vietnam 600
SE - Svezia 541
IN - India 340
IE - Irlanda 229
FR - Francia 192
RU - Federazione Russa 163
TG - Togo 159
CI - Costa d'Avorio 142
UA - Ucraina 139
ZA - Sudafrica 89
EE - Estonia 80
BG - Bulgaria 78
CH - Svizzera 50
JO - Giordania 49
ID - Indonesia 43
FI - Finlandia 42
BE - Belgio 39
CA - Canada 38
NL - Olanda 30
JP - Giappone 29
HK - Hong Kong 28
PT - Portogallo 28
ES - Italia 27
AT - Austria 26
PL - Polonia 24
HR - Croazia 21
TR - Turchia 21
AU - Australia 20
NG - Nigeria 17
TW - Taiwan 15
UZ - Uzbekistan 11
BR - Brasile 10
GR - Grecia 10
NZ - Nuova Zelanda 9
CZ - Repubblica Ceca 8
IR - Iran 8
SC - Seychelles 8
CL - Cile 7
IL - Israele 7
PH - Filippine 7
RO - Romania 7
DK - Danimarca 6
SA - Arabia Saudita 6
TH - Thailandia 6
KR - Corea 5
MA - Marocco 5
SI - Slovenia 5
EG - Egitto 4
PE - Perù 4
SM - San Marino 4
BD - Bangladesh 3
DZ - Algeria 3
EU - Europa 3
KE - Kenya 3
LT - Lituania 3
MT - Malta 3
AR - Argentina 2
BA - Bosnia-Erzegovina 2
CY - Cipro 2
KZ - Kazakistan 2
LB - Libano 2
LK - Sri Lanka 2
MX - Messico 2
MY - Malesia 2
NO - Norvegia 2
AL - Albania 1
CO - Colombia 1
HU - Ungheria 1
KH - Cambogia 1
ME - Montenegro 1
PA - Panama 1
PK - Pakistan 1
UG - Uganda 1
VE - Venezuela 1
Totale 15.533
Salva come PNG Salva come JPEG
Città #
Southend 1.209
Fairfield 849
Singapore 721
Chandler 651
Ashburn 466
Bologna 392
Dong Ket 391
Woodbridge 387
Wilmington 386
Seattle 364
Princeton 318
Houston 300
Cambridge 298
Santa Clara 256
Ann Arbor 254
Boardman 226
Dublin 224
Lomé 159
Abidjan 142
Redmond 140
Westminster 99
Berlin 93
Nanjing 86
Padova 78
Sofia 77
Beijing 70
Saint Petersburg 66
Milan 65
Jacksonville 60
Jinan 59
New York 56
San Diego 56
Turin 54
Florence 53
Falls Church 51
London 50
Amman 49
Shenyang 47
Bremen 46
Rome 44
Los Angeles 42
Jakarta 41
Hebei 37
Bern 36
Brussels 36
Medford 36
Modena 36
Des Moines 35
Helsinki 34
Guangzhou 32
Nanchang 32
Boydton 30
Shanghai 29
Tianjin 28
Changsha 26
Zhengzhou 26
Jiaxing 25
Dearborn 24
Mülheim 24
Hangzhou 23
Biella 21
Bühl 21
Paris 21
Porto 20
Verona 20
Vienna 20
Chicago 19
Abeokuta 17
Cesena 17
Frankfurt am Main 17
Olalla 17
Redwood City 16
Shenzhen 16
Taizhou 16
Norwalk 15
Taipei 15
Miami 14
Toronto 14
Haikou 13
Messina 13
Ningbo 13
Central 12
Istanbul 12
San Francisco 12
Warsaw 12
Amsterdam 11
San Venanzo 11
Wuhan 11
Chengdu 10
Pune 10
Tokyo 10
Birmingham 9
Mercato Saraceno 9
Moscow 9
Frankfurt Am Main 8
Fuzhou 8
Hyderabad 8
Kunming 8
Lappeenranta 8
Monselice 8
Totale 10.565
Salva come PNG Salva come JPEG
Nome #
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. 439
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance 408
Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) 240
ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance 238
Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system 229
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 207
Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy 190
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies 184
Advancements in drug development for diarrhea-predominant irritable bowel syndrome 176
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems 176
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy. 168
Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. 160
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: beyond bleeding complications 159
Antimicrobials and the Risk of Torsades de Pointes. The Contribution from Data Mining of the US FDA Adverse Event Reporting System 154
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 151
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 148
Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis 147
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database 138
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 137
Clinically important drug-drug interactions in poly-treated elderly outpatients: A campaign to improve appropriateness in general practice 135
Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system 134
Pattern of drug use among preterm neonates: Results from an Italian neonatal intensive care unit 133
Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development 132
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System 132
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System 130
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis 129
Drug-induced Kounis syndrome: A matter of pharmacovigilance 128
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System 127
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database 127
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection 126
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping 125
Pro-arrhythmic potential of oral antihistamines (H1): Combining adverse event reports with drug utilization data across Europe 125
Targeting the arrhythmogenic substrate in atrial fibrillation: focus on structural remodeling 122
The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project 122
hERG-related drug toxicity and models for predicting hERG liability and QT prolongation 120
Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey 116
Association between the use of proton pump inhibitors and cardiovascular events: A note of caution 116
Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology. 114
Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis 112
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 112
The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. 112
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus 111
The hERG K+ channel: target and antitarget strategies in drug development. 111
Stroke, Migraine and Triptans: From Bedside to Bench 111
Mesenchymal stromal cell-based therapy: Regulatory and translational aspects in gastroenterology 111
Balancing the Need for Personalization of QT Correction and Generalization of Study Results: Going Beyond Thorough QT Studies 110
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 110
Apparato Gastroenterico 106
Phytoestrogens in postmenopause: the state of the art from a chemical, pharmacological and regulatory perspective 106
Antimicrobial-induced torsades de pointes: towards risk stratification by data mining of the FDA Adverse Event Reporting System. 106
Role of drugs and devices in patients at risk of sudden cardiac death. 106
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature 105
Are specific initiatives required to enhance prescribing of generic atypical antipsychotics in Scotland?: International implications. 104
Ceftolozane/tazobactam exposure in critically ill patients undergoing continuous renal replacement therapy: a PK/PD approach to tailor dosing 103
Macrolides and Torsadogenic Risk: Emerging Issues from the FDA Pharmacovigilance Database 100
Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies 99
Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period. 98
Trends in antiarrhythmic drug use after marketing authorization of dronedarone: comparison between Emilia Romagna (Italy) and Sweden. 98
The beta3-adrenoceptor as a therapeutic target: current perspectives. 98
Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease 98
Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: Insight from a pharmacovigilance study 96
Serious Cutaneous Toxicities with Immune Checkpoint Inhibitors in the U.S. Food and Drug Administration Adverse Event Reporting System. 96
null 95
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 95
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 95
Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study 95
Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: An umbrella review 93
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). 92
Comment on: “Pharmacokinetics in Patients with Chronic Liver Disease and Hepatic Safety of Incretin-Based Therapies for the Management of Type 2 Diabetes Mellitus” 91
Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk 90
Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies 90
ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations 90
Breakthrough invasive fungal infections in liver transplant recipients exposed to prophylaxis with echinocandins vs other antifungal agents: A systematic review and meta-analysis 90
Infarto del miocardio, edema maculare e fratture associate ai glitazoni: analisi del database di segnalazione spontanea FDA_AERS 89
Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews 89
Impact of notoriety bias on reporting of pancreatitis with antidiabetics: the case of exenatide 88
Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice 88
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough? 88
Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region 88
QT shortening among suspected adverse drug reactions reported to the FDA: a case-by-case analysis 87
Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation 87
Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug–drug interactions through the FDA adverse event reporting system 87
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 85
No signal of interactions between influenza vaccines and drugs used for chronic diseases: a case-by-case analysis of the vaccine adverse event reporting system and vigibase 85
Glucagon-like peptide 1-based drugs and pancreatic safety. 84
Evidence for the hERG Liability of Antihistamines, Antipsychotics, and Anti-Infective Agents: A Systematic Literature Review From the ARITMO Project 84
Drug-induced liver injury: Towards early prediction and risk stratification 84
The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia 84
Influenza Vaccination and Myo-Pericarditis in Patients Receiving Immune Checkpoint Inhibitors: Investigating the Likelihood of Interaction through the Vaccine Adverse Event Reporting System and VigiBase 83
null 82
Progetto di monitoraggio della prescrizione di farmaci disease-modifying nella sclerosi multipla in Emilia-Romagna 81
Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome 81
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 79
Use and Perception of Phytoestrogens in Postmenopausal Women: Result of a Questionnaire-Based Survey 79
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System 79
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 78
Liver injury with direct-acting anticoagulants: Has the fog cleared? 77
Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems 77
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 77
Safety Meta-Analysis A Call for Appropriate Use of Disproportionality Measures from Spontaneous Reporting Systems 76
Totale 12.023
Salva come PNG Salva come JPEG
Categoria #
all - tutte 48.541
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 217
Totale 48.758
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.331 0 0 0 0 298 286 376 417 436 233 101 184
2020/20212.033 331 146 37 80 45 80 80 138 190 104 135 667
2021/20222.983 301 89 140 125 239 184 182 242 154 147 642 538
2022/20233.487 382 404 265 413 246 231 167 257 517 171 276 158
2023/20241.432 91 178 166 235 118 181 62 110 43 94 86 68
2024/20252.276 285 692 551 289 459 0 0 0 0 0 0 0
Totale 16.071